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of circulating CD4+CD31+ T cells (p= 0.432) or CD4+CD28+ T cells
(p = 0.155). Finally, we found that CD4+, CD4+CD31null,
CD4+CD28null, CD4+CD31+ and CD4+CD28+ were not correlated
with FMD (r = 0.034/p = 0.794, r =−0.031/p= 0.814, r =−0.061/
p= 0.645, r =−0.003/p=0.976, r = 0.045/p= 0.732 respectively) in
patients with UA.
In the present study we have shown that patients with UA are
characterized by a signiﬁcantly higher percentage of circulating
CD4+CD31null T cells and a signiﬁcantly impaired FMD than healthy
individuals. Our ﬁndings suggest that it is likely that the loss of the CD31
molecule from the surface of circulating CD4+ T cells characterizes the
appearance of a novel subpopulation of T cells that may affect
atherogenesis and potentially its complications. Moreover, we have
supported further the theory of the direct involvement of CD4+CD28null
T cells in plaque destabilization as the UA patients presented signiﬁcantly
higher frequencies of CD4+CD28null T cells. It seems that circulating
CD4+CD31null and CD4+CD28null T cells can lead to a poormechanical
endothelial response in patients with unstable angina.
In conclusion, in the present studywe found a higher level of Tcells
in patients with unstable angina and this may contribute to plaque
instability in these patients. However, the exact mechanisms linking
the loss of CD31 and CD28 molecules from CD4+ T cells with
endothelial dysfunction in unstable angina are still unclear andmany
more experimental studies are required to conﬁrm mechanistically
this association.
The authors report no relationships that could be construed as a
conﬂict of interest.
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Chronic Chagas heart disease affects approximately 30% of patients
infected by the protozoan Trypanosoma cruzi around 20 years after
infection. The clinical manifestations of this disease are malignant
arrhythmias [1], chronic systolic heart failure [2], sudden cardiac
death [3], and thromboembolism [4]. Tissue damage resulting from
inﬂammatory inﬁltrates and persistence of T. cruzi in myocardial
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tissue is involved in the pathogenesis of cardiomyopathy. However,
the precise pathogenic mechanism of Chagas' heart disease is not
completely elucidated [4,5].
The CC chemokine receptor 5 (CCR5) expressed by monocytes,
macrophages and TH1 cells is a receptor for the CCL3, CCL4 and CCL5
chemokines [6,7]. Genetic variants of the CCR5 gene may be involved
in the differential susceptibility for Chagas cardiomyopathy [8–10].
In this study, we investigated the relationship of the CCR5Δ32
(rs333) and CCR5 59029 A/G (rs1799987) polymorphisms of the CCR5
gene in patients with chronic Chagas' disease, with and without left
ventricular systolic dysfunction (LVSD); left ventricular ejection
fraction (LVEF) is currently the most important predictor of all-cause
mortality of patients with this condition [11].
This study was approved by the Research Ethics Committee of the
Medicine School in São José do Rio Preto (# 009/2011) and informed
consentwas obtained from all patients. A total of 168 consecutivemale
and female patients were enrolled from the Cardiomyopathy
Outpatient Service of Hospital de Base of the Fundação Faculdade de
Medicina de São José do Rio Preto. Anti-T. cruzi antibodies were
detected by immunosorbent assay (ELISA) according to the manufac-
turer's instructions (ELISAcruzi; bioMerieux S.A. Brazil).
Patients were divided into three groups according to the LVEF;
patients with LVEF N60%, between 60% and 40% and those with LVEF
b40% as calculated using the Teichholz' method were classiﬁed as
without, mild, and severe LVSD, respectively. The severe group was
deﬁned according to the Brazilian guidelines of severe chronic heart
disease [12]. For patients in which the LVEF was measured by
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radionuclide ventriculography, a LVEF N50% indicated normal left
ventricular systolic function, LVEF between 30% and 50% indicated
mild to moderate LVSD, and a LVEF b30% was consistent with severe
LVSD.
Genomic DNA was attained using a commercial kit for silica
column extraction (PureLink™ Genomic DNA Mini Kit, Invitrogen,
Carlsbad, California/USA) and following the manufacturer's instruc-
tions. The CCR5Δ32 polymorphism of the CCR5 gene was identiﬁed
by polymerase chain reaction (PCR), according to the protocol of
Huang et al. [13]. The polymorphism of the promoter region of the
CCR5 gene (CCR5-59029 A/G) was identiﬁed by PCR-restriction
fragment length polymorphism (PCR-RFLP) as described by McDer-
mott et al. [14]. Comparisonsof proportionsbetweengroupsweremade
by the chi-square test using the softwareGraphPad Instat (version 3.06).
Differences were considered statistically signiﬁcant for a p-value b 0.05.
The CCR5Δ32 polymorphismwas investigated in 168 patients: 152
(90.5%) were wild type homozygotes, and 16 (9.5%) heterozygotes.
Homozygotes for this deletion were not found. Table 1 shows data on
allele and genotype frequencies. The CCR5 59029 A/G polymorphism
was analyzed in 155 patients. The genotype frequencies were: AA
(39.4%), AG (36.1%) and GG (24.5%). The data on allele and genotype
frequencies are shown in Table 2.
The CCR5Δ32 deletion results in a non-functional receptor not
detected on the cell surface, whereas heterozygous individuals for this
polymorphism have reduced levels of CCR5 expression [15,16]. The
results of this study show no association of genotypes and alleles of
the CCR5Δ32 polymorphism between groups of patients with chronic
Chagas' disease. A study suggested that the CCR5/CCR5Δ32 genotype
can protect against inﬂammatory cardiomyopathy, a consequence of
the chronic phase of Chagas' disease [9] but this study did not conﬁrm
this due to the low frequency of the CCR5/CCR5Δ32 genotype.
The CCR5 59029 A/G polymorphism of the promoter region alters
the expression of CCR5 on the surface of leukocytes. It has been
demonstrated that the A allele has higher promoter activity in vitro
than the G allele and that the increased expression of CCR5 results
from the AA genotype [14,17]. The genotypes and alleles of the CCR5
59029 A/G polymorphism did not differ between the groups of
Chagas' disease patients included in this study.
Our results contrast with the results reported by other studies.
Calzada et al. [8] found a higher frequency of the AG genotype and the
presence of the G allele in asymptomatic patients compared to
patients with cardiomyopathy. These authors suggested that the G
allele could protect against the development of Chagas cardio-
myopathy. Another study found a low frequency of the GG genotype
in patients with arrhythmias compared to asymptomatic patients [9].
These authors suggested that this genotype may protect against the
development of cardiomyopathy symptoms in individuals infected
with T. cruzi [9].
The results of the work of Flórez et al. [10] did not show any
signiﬁcant association between the CCR5 59029 A/G polymorphism
and protection against the development of Chagas' disease cardio-
myopathy, however, the development of Chagas disease cardiomyo-
pathy was associated with the HHA haplotype in which the G allele
was present. The authors suggest that in this type of study it may be
more appropriate to estimate haplotypes, as several polymorphisms
in the promoter region may inﬂuence the CCR5 receptor expression
levels and the cell type in which it is expressed [10,18].
In this study, the heart disease was evaluated according to the
degree of LVSD. In other studies, the aim was not to investigate any
possible relationship between CCR5Δ32 and CCR5 59029 A/G poly-
morphisms and left ventricular impairment, and so the criteria to
classify patients were different [8–10]. These distinct strategies may
have contributed to the discrepant results reported in this study
compared to other research.
In conclusion, the CCR5Δ32 (rs333) and CCR5 59029 A/G
(rs1799987) polymorphisms had no relationship with LVSD in
patients with chronic Chagas' heart disease in this study population.
Thus, these polymorphisms do not seem to inﬂuence left ventricular
impairment.
The authors declare no conﬂicts of interest.
This work was supported by FAPESP (São Paulo Research
Foundation) Grants #2011/08075-4, #2011/19439-7, #2012/20735-2,
and #2012/05580-2 and Brazilian Ministry of Education—CAPES PhD
Scholarship (Coordination of Improvement of Higher Education
Personnel, Brazil). Many thanks to Igor Isnardi Barreto for technical
support (FAPESP #2012/03679-1) and to David Hewitt to proofread
the English. Many thanks to Professor Stephen Henry, Auckland
University of Technology, New Zealand, by the comments.
References
[1] Bestetti RB, Santos CR, Machado-Júnior OB, et al. Clinical proﬁle of patients with
Chagas' disease before and during sustained ventricular tachycardia. Int J Cardiol
1990;29:39–46.
[2] Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA,
Cordeiro JA. Effects of B-blockers on outcome of patients with Chagas'
cardiomyopathy with chronic heart failure. Int J Cardiol 2011;151:205–8.
[3] Bestetti RB, Cardinalli-Neto A. Sudden cardiac death in Chagas' heart disease in the
contemporary era. Int J Cardiol 2008;131:9–17.
[4] Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy—where do we stand after a
hundred years? Prog Cardiovasc Dis 2010;52:300–16.
[5] Cunha-Neto E, Nogueira LG, Teixeira PC, et al. Immunological and non-
immunological effects of cytokines and chemokines in the pathogenesis of
chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz 2009;104(Suppl
I):252–8.
[6] Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in
primary, effector, and memory immune responses. Annu Rev Immunol
2000;18:593–620.
[7] Szpakowska M, Fievez V, Arumugan K, van Nuland N, Schmit JC, Chevigné A.
Function, diversity and therapeutic potential of the N-terminal domain of human
chemokine receptors. Biochem Pharmacol 2012;84:1366–80.
Table 1
Genotype and allele frequencies of the CCR5Δ32 polymorphism in Chagas' disease
patients with normal left ventricular systolic function, andmild tomoderate, and severe
left ventricular systolic dysfunction.
Genotypes Normal Mild/moderate
LVSD
Severe LVSD χ2 DF pa
CCR5Δ32 No. % No. % No. %
CCR5/CCR5 78 (91.8) 40 (93.0) 34 (85.0) 1.880 2 0.391
CCR5/CCR5Δ32 7 (8.2) 3 (7.0) 6 (15.0)
Total 85 (100.0) 43 (100.0) 40 (100.0)
Alleles
CCR5 163 (95.9) 83 (96.5) 74 (92.5) 1.786 2 0.409
CCR5Δ32 7 (4.1) 3 (3.5) 6 (7.5)
a Calculated by χ2; LVSD: Left ventricular systolic dysfunction; DF: Degree of freedom.
Table 2
Genotype and allele frequencies of the CCR5 59029 A/G polymorphism in Chagas'
disease patients with normal left ventricular systolic function, and mild to moderate,
and severe left ventricular systolic dysfunction.
Genotypes Normal Mild/moderate
LVSD
Severe
LVSD
χ2 DF pa
CCR5 59029A/G No. % No. % No. %
AA 30 (37.5) 16 (40.0) 15 (42.9) 0.302 2 0.860
AG 29 (36.3) 14 (35.0) 13 (37.1) 0.038 2 0.981
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Alleles
A 89 (55.6) 46 (57.5) 43 (61.4) 0.671 2 0.715
G 71 (44.4) 34 (42.5) 27 (38.6)
a Calculated by χ2; LVSD: Left ventricular systolic dysfunction; DF: Degree of freedom.
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Cardiac sarcoidosis is rare but being increasingly recognized
because of poor prognosis [1]. Steroids are the mainstay of treatment
for cardiac sarcoidosis to resolve activemyocardial inﬂammation [2,3].
Gallium-67 citrate (67Ga) scintigraphy and 18F-ﬂuoro-2-deoxyglucose
(FDG) positron emission tomography (PET) are used to evaluate the
response to steroid treatment [4,5]. However, it remains unknown
whether steroid treatment can completely resolve active myocardial
inﬂammation evaluated by these imaging modalities and whether the
resolution of inﬂammation is associated with an improvement in left
ventricular (LV) function. The aim of this study was to determine the
efﬁcacy of steroid treatment for resolving inﬂammation and improv-
ing LV function and to elucidate predictors of the functional responder
to steroid treatment in patients with cardiac sarcoidosis.
The study population consisted of 30 consecutive patients with
cardiac sarcoidosis who had positive myocardial uptake of 67Ga or
18F-FDG at baseline between December 1994 and November 2012.
18F-FDG PET was performed in 5 patients who had no positive
myocardial uptake of 67Ga, after patients were instructed to fast for
at least 12 h, blood glucose level was determined to ensure a level of
b150 mg/dl, and unfractionated heparin was administrated. Car-
diac sarcoidosis was diagnosed on the basis of guidelines of the
Japanese Ministry of Health andWelfare [6], and guidelines revised
in 2006 by the Japan Society of Sarcoidosis and Other
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Table 1
Clinical characteristics.
All patients (n = 30)
Age (year) 61 ± 12
Female 20 (67)
Extracardiac organ involvement
Lung 18 (60)
Skin 5 (17)
Eye 12 (40)
Other 6 (20)
Number of organ involvement
1 site 6 (20)
2 sites 13 (43)
≥3 sites 11 (37)
NYHA functional class III or IV 10 (33)
LV end-diastolic volume (ml/m2) 83 ± 19
LV end-systolic volume (ml/m2) 49 ± 23
LV ejection fraction (%) 43 ± 15
High-degree heart block 13 (43)
Sustained ventricular tachycardia 12 (40)
Angiotensin-converting enzyme (IU/l) 14.9 ± 6.7
B-type natriuretic peptide (pg/ml) 361 ± 455
Initial dose of prednisone 30 mg/40 mg 27 (90)/3 (10)
Period of initial dose of prednisone (week) 5.6 ± 3.5
Maintenance dose of prednisone 5 to 7.5 mg/7.6 to 10 mg 16 (53)/14 (47)
Beta-blocker use 20 (67)
Cardiac resynchronization therapy 7 (23)
Data are presented as means ± standard deviation or numbers (%) of patients.
High-degree heart block includes complete atrioventricular block and Mobitz II block.
NYHA, New York Heart Association; LV, left ventricular.
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